Skip to main content
Erschienen in: Pediatric Cardiology 6/2019

08.06.2019 | Original Article

Outcomes of Myocarditis in Patients with Normal Left Ventricular Systolic Function on Admission

verfasst von: Spencer B. Barfuss, Ryan Butts, Kenneth R. Knecht, Adriana Prada-Ruiz, Ashwin K. Lal

Erschienen in: Pediatric Cardiology | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

The objective of this study was to describe a cohort of patients with clinical myocarditis and normal left ventricular (LV) systolic function on admission. A retrospective chart review at seven tertiary pediatric hospitals identified patients aged < 19 years admitted with an ICD-9 code of myocarditis between 2008 and 2012. Patients were excluded if admission LV systolic ejection fraction was < 50%, fractional shortening (FS) was < 28% or if the admitting or consulting cardiologist did not suspect myocarditis. A total of 75 patients met inclusion criteria. The median age was 15.5 years with an Interquartile Range (IQR) of 13.6–16.6. 33% were female. Patients presented most commonly with chest pain (75%) and dyspnea (24%). On admission, median B-type natriuretic peptide (BNP) was 132 pg/mL (IQR 57–689) and median troponin I (TnI) was 8.4 ng/mL (IQR 2.0–20.3). Electrocardiogram revealed ST elevation in the majority (55%). Magnetic resonance imaging was obtained on 40%, with 63% of those showing evidence of inflammation. Therapies included inotropic support (15%), mechanical ventilation (12%), antiarrhythmic medications (9%), and Extracorporeal Membrane Oxygenation (5%). Those with poor outcomes were noted to have significantly higher BNP, TnI, and creatine kinase levels on presentation. One patient was transplanted and 35% were discharged on heart failure medications. At one year follow-up one patient had died of unspecified causes, 15% required readmission for cardiac reasons, and 21% continued on heart failure medications. The risk associated with clinical myocarditis in the setting of normal ventricular function at presentation may be higher than previously suspected.
Literatur
1.
Zurück zum Zitat Ghelani SJ, Spaeder MC, Pastor W, Spurney CF, Klugman D (2012) Demographics, trends, and outcomes in pediatric acute myocarditis in the United States, 2006 to 2011. Circ Cardiovasc Qual Outcomes 5:622–627CrossRef Ghelani SJ, Spaeder MC, Pastor W, Spurney CF, Klugman D (2012) Demographics, trends, and outcomes in pediatric acute myocarditis in the United States, 2006 to 2011. Circ Cardiovasc Qual Outcomes 5:622–627CrossRef
2.
Zurück zum Zitat Kuhn B, Shapiro ED, Walls TA, Friedman AH (2004) Predictors of outcome of myocarditis. Pediatr Cardiol 25:379–384CrossRef Kuhn B, Shapiro ED, Walls TA, Friedman AH (2004) Predictors of outcome of myocarditis. Pediatr Cardiol 25:379–384CrossRef
3.
Zurück zum Zitat Sachdeva S, Song X, Dham N, Heath DM, DeBiasi RL (2015) Analysis of clinical parameters and cardiac magnetic resonance imaging as predictors of outcome in pediatric myocarditis. Am J Cardiol 115:499–504CrossRef Sachdeva S, Song X, Dham N, Heath DM, DeBiasi RL (2015) Analysis of clinical parameters and cardiac magnetic resonance imaging as predictors of outcome in pediatric myocarditis. Am J Cardiol 115:499–504CrossRef
4.
Zurück zum Zitat Thankavel PP, Mir A, Ramaciotti C (2014) Elevated troponin levels in previously healthy children: value of diagnostic modalities and the importance of a drug screen. Cardiol Young 24:283–289CrossRef Thankavel PP, Mir A, Ramaciotti C (2014) Elevated troponin levels in previously healthy children: value of diagnostic modalities and the importance of a drug screen. Cardiol Young 24:283–289CrossRef
5.
Zurück zum Zitat Kern J, Modi R, Atalay MK, Kochilas LK (2009) Clinical myocarditis masquerading as acute coronary syndrome. J Pediatr 154:612–615CrossRef Kern J, Modi R, Atalay MK, Kochilas LK (2009) Clinical myocarditis masquerading as acute coronary syndrome. J Pediatr 154:612–615CrossRef
6.
Zurück zum Zitat Kobayashi D, Aggarwal S, Kheiwa A, Shah N (2012) Myopericarditis in children: elevated troponin I level does not predict outcome. Pediatr Cardiol 33:1040–1045CrossRef Kobayashi D, Aggarwal S, Kheiwa A, Shah N (2012) Myopericarditis in children: elevated troponin I level does not predict outcome. Pediatr Cardiol 33:1040–1045CrossRef
7.
Zurück zum Zitat Schwartz MC, Wellen S, Rome JJ, Ravishankar C, Natarajan S (2013) Chest pain with elevated troponin assay in adolescents. Cardiol Young 23:353–360CrossRef Schwartz MC, Wellen S, Rome JJ, Ravishankar C, Natarajan S (2013) Chest pain with elevated troponin assay in adolescents. Cardiol Young 23:353–360CrossRef
8.
Zurück zum Zitat Butts RJ, Boyle GJ, Deshpande SR, Gambetta K, Knecht KR, Prada-Ruiz CA, Richmond ME, West SC, Lal AK (2017) Characteristics of clinically diagnosed pediatric myocarditis in a contemporary multi-center cohort. Pediatr Cardiol 38:1175–1182CrossRef Butts RJ, Boyle GJ, Deshpande SR, Gambetta K, Knecht KR, Prada-Ruiz CA, Richmond ME, West SC, Lal AK (2017) Characteristics of clinically diagnosed pediatric myocarditis in a contemporary multi-center cohort. Pediatr Cardiol 38:1175–1182CrossRef
Metadaten
Titel
Outcomes of Myocarditis in Patients with Normal Left Ventricular Systolic Function on Admission
verfasst von
Spencer B. Barfuss
Ryan Butts
Kenneth R. Knecht
Adriana Prada-Ruiz
Ashwin K. Lal
Publikationsdatum
08.06.2019
Verlag
Springer US
Erschienen in
Pediatric Cardiology / Ausgabe 6/2019
Print ISSN: 0172-0643
Elektronische ISSN: 1432-1971
DOI
https://doi.org/10.1007/s00246-019-02127-x

Weitere Artikel der Ausgabe 6/2019

Pediatric Cardiology 6/2019 Zur Ausgabe

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.